The Power of Truth^® has been released for sale and assignment to a conservative pro-American news outlet, cable network, or other media outlet that wants to define and brand its operation as the bearer of the truth, and set itself above the competition.

In every news story the audience hears of censorship, speech, and the truth. The Power of Truth^® has significant value to define an outlet, and expand its audience. A growing media outlet may decide to rebrand their operation The Power of Truth^®. An established outlet may choose to make it the slogan distinguishing their operation from the competition. You want people to think of your outlet when they hear it, and think of the slogan when they see your company name. It is the thing which answers the consumer's questions: Why should I choose you? Why should I listen to you? Think:

What’s in your wallet -- Capital One
The most trusted name in news – CNN
Fair and balanced - Fox News
Where’s the beef -- Wendy’s
You’re in good hands -- Allstate
The ultimate driving machine -- BMW

The Power of Truth^® is registered at the federal trademark level in all applicable trademark classes, and the sale and assignment includes the applicable domain names. The buyer will have both the trademark and the domains so that it will control its business landscape without downrange interference.

Contact: Truth@ThePowerOfTruth.com

Sidebar

Magazine menu

The Power of Truth^®

Friday, November 15, 2024

Endovascular catheter opens blocked arteries deep within lungs

Health

A new endovascular catheter, recently approved by the U.S. Food and Drug Administration (FDA), is paving the way to more effective and safe treatment for acute pulmonary embolism. Already shown to be effective for reducing blockages in lung arteries, new research shows that this catheter also reduces blockages in the smaller segmental pulmonary artery branches. These branches are ultimately responsible for oxygenating the blood in the lungs. The new study, which was part of the National Institutes of Health-sponsored multicenter RESCUE clinical trial, further showed a correlation between decreased numbers of blockages in the small lung arteries and functional recovery of the right ventricle of the heart, which pumps blood into the main pulmonary artery of the lungs. Compared to other devices, the BASHIR™ catheter also had significantly lower bleeding rates, a key advance in acute pulmonary embolism treatment. The findings are described in JACC: Advances.

A new endovascular catheter, recently approved by the U.S. Food and Drug Administration (FDA), is paving the way to more effective and safe treatment for acute pulmonary embolism. Already shown to be effective for reducing blockages in lung arteries, new research shows that this catheter also reduces blockages in the smaller segmental pulmonary artery branches. These branches are ultimately responsible for oxygenating the blood in the lungs. The new study, which was part of the National Institutes of Health-sponsored multicenter RESCUE clinical trial, further showed a correlation between decreased numbers of blockages in the small lung arteries and functional recovery of the right ventricle of the heart, which pumps blood into the main pulmonary artery of the lungs. Compared to other devices, the BASHIR™ catheter also had significantly lower bleeding rates, a key advance in acute pulmonary embolism treatment. The findings are described in JACC: Advances.

Read more https://www.sciencedaily.com/releases/2023/12/231204135110.htm